Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Completes Patient Enrollment For Second Cohort In Phase II CIN 2/ 3 Study 0 comments
    Jun 7, 2012 5:20 PM | about stocks: ADXS

    Advaxis, a clinical-stage biotech company developing immunotherapies for cancer and infectious diseases, today announced it has completed the enrollment of 40 patients for the second of three dose cohorts in the phase II study to assessment the safety and efficacy of ADXS-HPV for the treatment of intraepithelial neoplasia (CIN) 2/3.

    Patients enrolled for cohort 2 were randomized 3:1 to ADXS-HPV (3 doses at 3.3×108 cfu) or placebo, which is six times higher than that administered in cohort 1.

    Patients will undergo observation for six months after the last dose, after which they will undergo the standard of care surgery (LEEP) required for the treatment of this disease.

    Once all patients have completed LEEP, the company will report study results.

    "Advaxis continues to meet major milestones in our clinical development plan," Dr. John Rothman, EVP of Science & Operations at Advaxis stated in the press release. "We look forward to assessing the results of the second cohort of this study and to advancing the development of ADXS-HPV for the treatment of HPV-associated diseases."

    The company in February 2012 announced the results from the first cohort of the trial, which consisted of 41 patients randomized 3:1 ADXS-HPV (3 doses at 5×107 cfu) or placebo. Results demonstrated that 29 percent of the patients experienced side effects that were related, or were possibly related, to the treatment; no serious adverse events were experienced; 52 percent of CIN 2/3 lesions regressed from CIN 2/3 to CIN 1 or normal in the ADXS-HPV arm; and 40 percent of CIN 2/3 lesions spontaneously regressed in the placebo arm.

    For more information visit advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.